An experimental drug called RSO-021 controlled disease in 67% of patients at 12 weeks in a small phase 1 trial for relapsed pleural mesothelioma, according to a study published in Nature Communications. The drug is not approved by the FDA, is not available to U.S. patients outside research studies, and was tested in 15 patients in the United Kingdom.
The paper appeared in July and was recirculated this month in a ScienceDaily research summary, bringing renewed attention to a cancer with few good treatment options. Mesothelioma is most often caused by asbestos exposure.
